Incidence of serous tubal intraepithelial carcinoma (STIC) by algorithm classification in serous ovarian tumor associated with PAX8 expression in tubal epithelia: A study of single institution in Japan

International Journal of Gynecological Pathology

Volumn 34, Issue 1, 2015, Pages 9-18

  Munakata, Satoru ^a   Yamamoto, Toshiya ^a  

^a Sakai City Medical Center   (Japan)

Author keywords

Immunohistochemistry; Japanese institution; PAX8; Serous tubal intraepithelial carcinoma; Serousovarian tumor

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; TRANSCRIPTION FACTOR PAX8; PAIRED BOX TRANSCRIPTION FACTOR; PAX8 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRENNER TUMOR; CANCER INCIDENCE; CARCINOGENESIS; CELL PROLIFERATION; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; ENDOMETRIOID CARCINOMA; FALLOPIAN TUBE EPITHELIUM; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SECRETORY CELL; SECRETORY CELL PROLIFERATION; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; TUMOR CLASSIFICATION; UTERINE TUBE; UTERINE TUBE CARCINOMA; AGE; ALGORITHM; CARCINOMA IN SITU; CELL TRANSFORMATION; CLASSIFICATION; COMPARATIVE STUDY; EPITHELIUM; GENE EXPRESSION REGULATION; GENETICS; INCIDENCE; METABOLISM; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PATHOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALGORITHMS; CARCINOGENESIS; CARCINOMA IN SITU; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIUM; FALLOPIAN TUBES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INCIDENCE; JAPAN; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PAIRED BOX TRANSCRIPTION FACTORS; RETROSPECTIVE STUDIES;

EID: 84918831088     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000108     Document Type: Article

References (36)

1. Ushijima K. Current status of gynecologic cancer in Japan. J Gynecol Oncol 2009;20:67-71.
2. Kurman RJ, Shih LM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer. Shifting the paradigm. Hum Pathol 2011;42:918-31.
3. Finch A, Beiner M, Lubinski J, et al. Salgingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296:185-92.
4. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Caner Inst 2009;101:80-7.
5. Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Women Health 2012;8: 543-55.
6. Piek JMJ, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-6.
7. Kauff ND, Satagopan JM, Robson MF, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Eng J Med 2002;346:1609-15.
8. Olopade OI, Artioli G. Efficacy of risk-reducing salpingooophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 2004;10:S5-9.
9. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingooophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005;23:127-32.
10. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006;100:58-64.
11. Leunen K, Legius E, Moerman P, et al. Prophylactic salpingooophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia. Int J Gynecol Cancer 2006;16:183-8.
12. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230-6.
13. Crum CP, Dropkin R, Kindelberger D, et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2007;5:35-44.
14. Carlson JW, Jarboe EA, Kindelberger D, et al. Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int J Gynecol Pathol 2010;29:310-4.
15. Visvanathan K, Vang R, Shaw P, et al. Diagnosis of serous tubal intraepithelial carcinoma (STIC) based on morphologic and immunohistochemical features. A reproducibility study. Am J Surg Pathol 2011;35:1766-75.
16. Vang R, Visvanathan K, Gross A, et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol 2012;31:243-53.
17. Ozcan A, Shen SS, Hamilton C, et al. PAX8 expression in nonneoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol 2011; 24:751-64.
18. Laury AR, Ning G, Quick CM, et al. Fallopian tube correlates of ovarian serous borderline tumors. Am J Surg Pathol 2011; 35:1759-65.
19. Singer G, Oldt R, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-6.
20. Sieben NLG, Macropoulos P, GMJM Roemen, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004;202: 336-40.
21. Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/ MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998;58: 2095-7.
22. Catasus L, Bussaglia E, Rodrguez I, et al. Molecular genetic alteration in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004;35:1360-8.
23. Campbell IG, Russell SE, Choong DYH, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81.
24. Jones S, Wang TL, Shih LM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330:228-31.
25. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-43.
26. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010;221:49-56.
27. Kurman RJ, Shih LM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer. Shifting the paradigm. Hum Pathol 2011;42:918-31.
28. Casagrande JT, Pike MC, Ross RK, et al. "Incessant ovulation" and ovarian cancer. Lancet 1979;2:170-3.
29. Barber HRK, eds. Ovarian Carcinoma, Etiology, Diagnosis, and Treatment.; 3rd ed New York, Berlin, Heidelberg, London, Paris, Tokyo, Hong Kong, Barcelona, Budapest: Springer- Verlag 1993.
30. Brewer MA, Johnson K, Follen M, et al. Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 2003;9:20-30.
31. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 873030 controls. Lancet 2008;371:303-14.
32. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2003;23:41-4.
33. Maeda D, Ota S, Takazawa Y, et al. Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases. Vichows Arch 2010;457: 597-608.
34. Tang S, Onuma K, Deb P, et al. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int J Gynecol Pathol 2012; 31:103-10.
35. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161-9.
36. Poleev A, Fickensher H, Mundlos S, et al. PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms tumors. Development 1992;116: 611-23.